Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hypertension 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms 1Non-alcoholic Fatty Liver Disease 1Lymphoma, Follicular 1Lymphoma 1Hematologic Neoplasms 1Dyspnea 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Radiotherapy 29Cisplatin 12Amifostine 11Radiotherapy, Intensity-Modulated 7Paclitaxel 7Carboplatin 7Etoposide 5Radiosurgery 4Donepezil 4Brachytherapy 4Bevacizumab 4sargramostim 3Surgical Procedures, Operative 3Mental Status and Dementia Tests 3Filgrastim 3Diet Therapy 3Blood Specimen Collection 3Radiation Dose Hypofractionation 2Radiation 2Proton Therapy 2Magnetic Resonance Spectroscopy 2Low-Level Light Therapy 2Lithium 2Hyperbaric Oxygenation 2Heavy Ion Radiotherapy 2Fluorouracil 2Fibroblast Growth Factor 7 2Dexamethasone 2Chemotherapy, Adjuvant 2Androgen Antagonists 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Radiation Injuries × Lisinopril × Clear all
NCT05530655 2026-01-13

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester

Phase EARLY_PHASE1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡